novo nordisk nvo news - Search News

Novo Nordisk Stock Rises

Investopedia on MSN · 1d

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Hosted on MSN · 19h

UBS Upgrades Novo Nordisk A (NVO)

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.

Bernstein Issues Mkt Perform Rating for Novo Nordisk A/S (NVO) Stock

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a low of $84.

11hon MSN

Novo, Eli Lilly to dominate global pharma sales in 2025: report

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

17h

International Assets Investment Management LLC Cuts Position in Novo Nordisk A/S (NYSE:NVO)

International Assets Investment Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 98 ...

10d

Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

1d

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

1don MSN

Novo Nordisk, Valo Health expand drug discovery deal

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

1don MSN

This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results